Cigna Group Option Alert: Jan, 2027 $280 Calls Sweep (7) above Ask!: 1432 vs 1708 OI

Cigna Group Option Alert: Jan, 2027 $280 Calls Sweep (7) above Ask!: 1432 @ $69.8 vs 1708 OI; Ref=$307.03

Cigna Group (NYSE:CI) Stock

THE CIGNA GROUP

Cigna Group

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense (current contract through 2029), and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of December 2024.

Cigna

The Cigna Group

Citizens, Inc. Class A Common Stock ($1.00 Par)

Citizens Inc

CHINA MENGNIU DAIRY CO by China Mengniu Dairy Co., Ltd.

China Mengniu Dairy Co Ltd

CHINA MENGNIU DARY UN/ADR by China Mengniu Dairy Co., Ltd.

CHAMPION IRON LTD by Champion Iron Limited

Champion Iron Ltd

CHINA SCORE INC by China Score, Inc.

Grupo Cibest S.A. American Depositary Shares each representing four Preferred Shares

Grupo Cibest SA

COMML INTL BK S/ADR by Commercial International Bank Ltd.

Commercial International Bank (Egypt) CIB

CIB MARINE BANCSHARES by CIB Marine Bancshares, Inc.

CIB Marine Bancshares Inc

COMMUTY INV BANCORP INC by Community Investors Bancorp, Inc.

Community Investors Bancorp Inc

First Trust NASDAQ Cybersecurity ETF

CIBL Inc

CION Investment Corporation 7.50% Notes due 2029

CHINA CONSTR BANK H by China Construction Bank Corp.

China Construction Bank Corp

CHINA CONSTR BK UNSP/ADR by China Construction Bank Corp.

SMS ALTERNATIVES INC by SMS Alternatives Inc.

SMS Alternatives Inc

COSCO SHIPPING HLDGS CO by COSCO SHIPPING Holdings Co Ltd.

COSCO SHIPPING Holdings Co Ltd

COSCO SHP HLDG UNSP/ADR by COSCO SHIPPING Holdings Co Ltd.

CONCEPCION INDUSTRIAL CRP by CONCEPCION INDUSTRIAL CORP

Victory Portfolios II VictoryShares International High Div Volatility Wt

CLAL INSURANCE ENTERPRISE by CLAL INSURANCE ENTERPRISES HOLDINGS LTD.

Ciena Corp

CHIERU CO LTD by CHIERU CO LTD.

CORPORACION INTERAMER B by Corporacion Intramericano Entretenimiento S.A.

Corporacion Interamericana de Entretenimiento SAB de CV

MFS Intermediate High Income Fund Common Stock

Mfs Intermediate High Income Fund

Cipher Mining Inc

Comp En De Mn Cemig ADS American Depositary Shares

Cia Energetica DE Minas Gerais - Cemig

Comp En De Mn Cemig ADS American Depositary Receipts

Colliers International Group Inc. - Subordinate Voting Shares

Colliers International Group Inc

Concorde International Group Ltd - Class A Ordinary Shares

Concorde International Group Ltd

CI Games SE

CHINA MERCHANTS BK CO H by China Merchants Bank Co., Ltd.

China Merchants Bank Co Ltd

CHINA MRCHNTS BK UNSP/ADR by China Merchants Bank Co., Ltd.

CB INDUS PRODUCT HLDG BHD by CB Industrial Product Holding BHD

BlackRock Enhanced Large Cap Core Fund, Inc. Common Stock

Blackrock Enhanced Cap&Inc Fund, Inc

CITIC SECURITIES CO LTD H by Citic Securities Co., Ltd.

CITIC Securities Co Ltd

CITIC SECURITIES UNSP/ADR by Citic Securities Co., Ltd.

Tianci International, Inc. - Common Stock

Tianci International Inc

Credit Suisse Asset Management Income Fund, Inc. Common Stock

Credit Suisse Asset Mgmt Income Fund Inc

VictoryShares International Volatility Wtd ETF

CHINA LIFE INS CO H SHS by China Life Insurance Company Limited

China Life Insurance Co Ltd

CAROLINA MILLS INC by Carolina Mills, Inc.

Chimera Investment Corporation Common Stock

Chimera Investment Corp

CIMB GROUP HLDGS BHD ORD by CIMB Group Holdings BHD

CIMB Group Holdings Bhd

CIMC ENRIC HLDGS LTD ORD by CIMC Enric Holdings Ltd.

CIMC Enric Holdings Ltd

Chimera Investment Corporation 9.000% Senior Notes due 2029

Chimera Investment Corporation 9.250% Senior Notes due 2029

CIMAREX ENERGY 8 1/8 PFD by Cimarex Energy Co.

Chimera Investment Corporation 8.00% Series A Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 8.00% Series B Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 7.75% Series C Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 8.00% Series D Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

CHINA INDUSTRIAL GRP INC by China Industrial Group, Inc.

Cincinnati Financial Corporation - Common Stock

Cincinnati Financial Corp

Cingulate Inc

COINSILIUM GROUP LTD ORD by Coinsilium Group Ltd.

Coinsilium Group Ltd

CHINA TAIPING INS HLD ORD by China Taiping Insurance Holdings Co Ltd.

China Taiping Insurance Holdings Co Ltd

CI&T Inc

CRUCIAL INNOVATIONS CORP by CRUCIAL INNOVATIONS CORP.

City Office REIT Inc

CREATE MEDIC CO LTD by Create Medic Company Ltd.

Create Medic Co Ltd

CION Invt Corp

CENTRAL IRON ORE LIMITED by CENTRAL IRON ORE LIMITED

Central Iron Ore Ltd

Cielo SA ADR

City Office REIT, Inc. 6.625% Series A Cumulative Redeemable Preferred Stock

CORRELATE ENERGY CORP by Correlate Energy Corp.

Correlate Energy Corp

JPMorgan Exchange-Traded Fund Trust Sustainable Consumption ETF

Cirus Foundation

CirTran Corp

Ciscom Corp

CHINA STEEL CP S/ADR 144A by China Steel Corp.

China Steel Corp

CISO Global Inc

C3is Inc

CHINA STEEL CORP S/GDR by China Steel Corp.

COSCO SHIPPING DEV CO LTD by Cosco Shipping Development Co Ltd.

Cosco Shipping Development Co Ltd

COSCO SHIP DEV UNSP/ADR by Cosco Shipping Development Co Ltd.

CARTICA ACQUISITION CORP L ASHS

CARTICA ACQUISITION CORP USD 1 CL A SHS & 1/2 RED WT EXP

CARTICA ACQUISITION CORP RED WTS

CRITICAL INFRASTUCTRE TCH by Critical Infrastructure Technologies Ltd.

Critical Infrastructure Technologies Ltd

AVALON CORRECTIONAL INC by Avalon Correctional Services, Inc.

Manchester City Fan Token

CITIZENS BANCSHARES CP SC by Citizens Bancshares Corp South Carolina

Citizens Bancshares Corp

Civilization

Civista Bancshares Inc

Civitas Resources Inc

Civitas Resources Inc Warrants (20/01/2026)

Civitas Resources Inc Warrants (20/01/2025)

CTR INVTS&CNSLTNG INC by CTR Investments & Consulting, Inc.

CTR Investments & Consulting Inc

CHINA INDL WASTE MGMT INC by China Industrial Waste Management, Inc.

China Industrial Waste Management Inc

CITZNS FINCL CORP W VA by Citizens Financial Corp. (WV)

Citizens Financial Corp WV

Compx International Inc

CaixaBank SA

CI Financial Corp

COMPASS EMP FDS TR DEVELOPED 500 ENHANCED VOLATILITY WEIGHTED INDEX ETF

CITZNS HOLDINGS CO MISS by Citizens Holding Co.

Citizens Holding Co

<a href="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics">https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics</a>

News

General

CLOV

EHTH

ELEV

GOCO

'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill'- Bloomberg

<a href="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true</a>

'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill' -Bloomberg

RBC Capital analyst Ben Hendrix reiterates Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Outperform and maintains $371 price target.

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Outperform on Cigna Group, Maintains $371 Price Target

Barclays analyst Andrew Mok maintains Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and raises the price target from $382 to $385.

Barclays Maintains Overweight on Cigna Group, Raises Price Target to $385

Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 15 years by 3.91% on an annualized basis producing an average annual return of 16.06%. Currently, Cigna Group has a market capitalization of $85.84 billion. 
Buying $100 In CI: If an investor had bought $100 of CI stock 15 years ago, it would be worth $929.38 today based on a price of $316.64 for CI at the time of writing.
<h3>Cigna Group's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748648720_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Cigna Group 15 Years Ago Would Be Worth Today

On May 7, the Ninth Circuit <a href="https://www.benzinga.com/topic/ftc" target="_blank" rel="noreferrer noopener">affirmed the decision</a> of the United States District Court for the Northern District of California, FTC versus Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), denying the Commission&#8217;s application for a preliminary injunction to block Microsoft&#8217;s $69 billion acquisition of Activision Blizzard, Inc.  
The Commission has now determined that the public interest is best served by dismissing the administrative litigation <a href="https://www.ftc.gov/legal-library/browse/cases-proceedings/2210077-microsoftactivision-blizzard-matter" target="_blank" rel="noreferrer noopener">in this case</a>.
Also Read: <a href="https://www.benzinga.com/media/25/05/45541908/supermicro-eyes-texas-mississippi-for-ai-server-growth-as-microsoft-amazon-increase-spending" target="_blank" rel="noreferrer noopener">Supermicro Eyes Texas, Mississippi For AI Server Growth As Microsoft, Amazon Increase Spending</a>
Microsoft sold the Xbox gaming console and offered a video game subscription service called Xbox Game Pass and a cloud-based video game streaming service. The agency alleged that the deal would enable Microsoft to suppress competitors to its Xbox gaming consoles and its rapidly growing subscription and cloud-gaming business. The Commission withdrew the matter from adjudication in July 2023 and returned it to adjudication on Sept. 26, 2023. 
Recently, the FTC also dropped a lawsuit against PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) for allegedly <a href="https://www.benzinga.com/government/regulations/25/05/45582935/ftc-scraps-pepsico-price-discrimination-case-in-3-0-vote-marking-major-shift-as-trump-era-leadership-reverses-biden-crackdown" target="_blank" rel="noopener">offering preferential pricing</a> to major retailers like Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>). The case marked broader Biden administration efforts to target price discrimination.
The FTC also paused cases against CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), and UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) over pharmacy benefit manager practices, citing commissioner shortages after President Donald Trump&#8216;s personnel changes.
President Trump named FTC Commissioner Andrew Ferguson <a href="https://www.benzinga.com/markets/24/12/42428224/bitcoin-ethereum-dogecoin-mirror-stock-declines-ahead-of-crucial-inflation-data-release-top-analyst-says-buy-the-dip-predicts-275k-btc-target" target="_blank" rel="noopener">his choice</a> for FTC chair last December, replacing Lina Khan. This could potentially reshape the agency&#8217;s approach to tech regulation and antitrust enforcement.
Under Khan&#8217;s leadership, the federal firm has aggressively targeted tech giants, including&nbsp;Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>),&nbsp;Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and&nbsp;Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>).
Price Action: MSFT stock is down 1.06% at $450.31 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45565087/cramer-backs-marvell-again-as-ai-deals-with-amazon-microsoft-fuel-stock-surge" target="_blank" rel="noreferrer noopener">Cramer Backs Marvell Again As AI Deals With Amazon, Microsoft Fuel Stock Surge</a></li>
</ul>
Photo: Shutterstock

Legal

Tech

AMZN

GOOGL

MSFT

Microsoft Clears Major Hurdle As FTC Ends Effort To Block Activision Merger

Guggenheim analyst Jason Cassorla reiterates Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Buy and maintains $388 price target.

Guggenheim Reiterates Buy on Cigna Group, Maintains $388 Price Target

The Federal Trade Commission voted 3-0 on Thursday to dismiss a lawsuit against PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) that accused the beverage giant of offering preferential pricing to major retailers, marking a significant shift from former President Joe Biden-era corporate scrutiny under the President Donald Trump administration.
What Happened: The FTC dropped the case filed in January&#8217;s final days of the Biden administration, with NBC News <a href="https://www.nbcnews.com/business/business-news/biden-era-pepsi-price-discrimination-suit-dropped-ftc-rcna208635">reporting</a> that Chair Andrew Ferguson criticized it as &#8220;a nakedly political effort to commit this administration to pursuing little more than a hunch that Pepsi had violated the law.&#8221; 
Ferguson, who dissented when the case was originally filed as a commissioner, now leads the agency after President Trump fired two Democratic commissioners in March.
The original lawsuit alleged PepsiCo violated the <a href="https://www.benzinga.com/25/01/43063862/whats-going-on-with-pepsico-stock-todayhttps://www.benzinga.com/25/01/43063862/whats-going-on-with-pepsico-stock-today">Robinson-Patman Act</a> by providing unfair pricing advantages to Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) through promotional payments and advertising allowances not extended to competing retailers. 
PepsiCo welcomed the decision, stating it &#8220;has always and will continue to provide all customers with fair, competitive, and non-discriminatory pricing.&#8221; 
See Also: <a href="https://www.benzinga.com/25/05/45581873/top-amd-exec-bets-nearly-1-million-on-stocksignals-confidence-amid-buybacks-easing-tariffs-and-saudi-deal">Top AMD Exec Adds Nearly $1 Million Of The Chipmaker&#8217;s Stock: Signals Confidence Amid Buybacks, Easing Tariffs And Saudi Deal</a> Why It Matters: The case was part of broader Biden administration efforts targeting price discrimination, following a December action against Southern Glazer&#8217;s <a href="https://www.benzinga.com/25/01/43063862/whats-going-on-with-pepsico-stock-todayhttps://www.benzinga.com/25/01/43063862/whats-going-on-with-pepsico-stock-today">wine and spirits distributor</a>.
The <a href="https://www.benzinga.com/general/health-care/25/04/44627279/ftc-pauses-lawsuit-against-cvs-cigna-unitedhealths-pbms-amid-commissioner-shortage?utm_source=chatgpt.com">FTC also paused separate cases</a> against CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), and UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) over pharmacy benefit manager practices, citing commissioner shortages after Trump&#8217;s personnel changes. 
Image Via Shutterstock 
Read Also:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45581845/judge-blocks-trumps-mass-federal-layoffs-citing-need-for-congressional-approval">Judge Blocks Trump&#8217;s Mass Federal Layoffs, Citing Need For Congressional Approval</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Regulations

Politics

Markets

FTC Scraps PepsiCo Price Discrimination Case In 3-0 Vote, Marking Major Shift As Trump-Era Leadership Reverses Biden Crackdown

WIIM

ALHC

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Shares of health insurance stocks are trading lower after CMS announced a strategy to enhance and accelerate Medicare Advantage audits.

<h2>CMS Rolls Out Aggressive Strategy to Enhance and Accelerate Medicare Advantage Audits</h2>

Biotech

'CMS Rolls Out Aggressive Strategy To Enhance And Accelerate Medicare Advantage Audits; Agency Will Begin Auditing All Eligible Medicare Advantage Contracts Each Payment Year And Add Resources To Expedite Completion Of 2018 To 2024 Audits'

Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 20 years by 3.82% on an annualized basis producing an average annual return of 12.12%. Currently, Cigna Group has a market capitalization of $88.11 billion. 
Buying $100 In CI: If an investor had bought $100 of CI stock 20 years ago, it would be worth $987.54 today based on a price of $325.00 for CI at the time of writing.
<h3>Cigna Group's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747778415_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Cigna Group Stock In The Last 20 Years

After Donald Trump signed an <a href="https://www.benzinga.com/general/health-care/25/05/45384935/trump-again-promises-lower-drug-prices-by-cutting-out-middlemen-like-unitedhealth-cvs-will-it-work-this-time">executive order</a> slashing drug prices last week, experts have highlighted how pharmacy benefit managers (PBMs) could be hit the hardest despite pharmaceutical companies facing the potential of compressed margins amid poor pricing power.
What Happened: According to Thomas Shipp, the head of equity research at LPL Financial, the pressure that the <a href="https://www.benzinga.com/news/25/05/45389750/trump-claims-drug-price-crackdown-could-slash-your-prescription-costs-by-59-but-will-big-pharma-fight-it-again">pharmaceutical manufacturers</a> are facing to lower prices domestically, &#8220;has the potential to compress margins by eroding pricing power and would provide a significant headwind to drug manufacturer share prices.&#8221;
However, he explains that the &#8220;middlemen&#8221; or PBMs that facilitate drug distribution and negotiate with pharmaceutical drug manufacturers to lower prescription costs have come under scrutiny for opaque pricing practices, like retaining rebates from drug manufacturers and "spread pricing."
&#8220;PBMs pay pharmacies less than what they charge health plan participants for drugs,&#8221; he said.
Another April 15 <a href="https://www.benzinga.com/markets/25/04/44866755/mark-cuban-says-this-trump-healthcare-order-could-save-hundreds-of-billions">executive order</a> signed by Trump called for increased transparency into PBM fees and requested that the role of these middlemen be reevaluated.
CVS Caremark, owned by CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Express Scripts, owned by Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), and OptumRx, owned by UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), are the biggest PBM companies.
Shipp also underscored that PBM savings are expected, but direct price controls pose a longer-term risk for U.S.-heavy drugmakers. Transparency will reveal if PBM margin erosion can prevent deeper manufacturer cuts, he highlights.
&#8220;While many questions remain about how these executive orders will be implemented, after the initial news flow is digested, the net effect appears less detrimental to pharmaceutical drug manufacturers than to PBMs,&#8221; said Shipp.
&#8220;That said, reworking the way Americans buy their medicine is going to take a long time. Along the way, efforts to support direct-to-consumer sales will support both the manufacturers leading the charge and those they partner with for distribution,&#8221; he added.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/05/45465955/ark-invest-takes-swipe-at-mstr-mara-says-bitcoin-treasury-companies-dont-make-sense-fundin">Ark Invest Expert Takes Swipe At MSTR, MARA, Says &#8216;Bitcoin Treasury Companies Don&#8217;t Make Sense:&#8217; &#8216;Funding Purchases With Debt&#8230;Seems Like A Recipe For Disaster&#8217;</a>
Why It Matters: Meanwhile, the billionaire investor and Shark Tank fame, Mark Cuban, called PBMs a &#8220;racket&#8221; in an X post by explaining that they <a href="https://www.benzinga.com/personal-finance/25/04/44674382/mark-cuban-says-big-insurance-companies-and-pbms-control-healthcare-costs-everyone-has-to-kiss-their-a-and-accept-the-complications">negotiate rebates and not prices</a>.
&#8220;They negotiate rebates. Not prices. In fact, the big PBMs control more than 95pct of the rebate negotiations. Big brand Pharma companies can&#8217;t negotiate with anyone else. IMO, it&#8217;s a racket,&#8221; he said.
While the April 15 order calls for transparency in pricing, Cuban highlights that 30% of the $4.9 trillion in healthcare spending is attributed to the overhead insurance companies and pricing distortions big PBMs create.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">One of the great lies the big PBM industry tells us is that they are needed to negotiate lower prices. It&#39;s a lie. They negotiate rebates. Not prices. In fact, the big PBMs control more than 95pct of the rebate negotiations. Big brand Pharma companies can&#39;t negotiate with…
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1923880717420986860?ref_src=twsrc%5Etfw">May 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Here are the aforementioned PBMs operating companies that have performed in 2025.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Stocks</td>
<td>YTD Performance</td>
<td>One-Year Performance</td>
</tr>
<tr>
<td>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>41.41%</td>
<td>8.94%</td>
</tr>
<tr>
<td>Cigna Group. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)</td>
<td>16.92%</td>
<td>-3.73%</td>
</tr>
<tr>
<td>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-42.14%</td>
<td>-43.56%</td>
</tr>
</tbody>
</table>
</figure>
Here are a few pharma-linked ETFs for investors to consider.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>-0.28%</td>
<td>-4.66%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-1.20%</td>
<td>-2.03%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-3.45%</td>
<td>-0.83%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-4.83%</td>
<td>-1.70%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>11.10%</td>
<td>1.65%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-6.51%</td>
<td>-6.89%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-23.63%</td>
<td>-24.07%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, ended higher on Friday. The SPY was up 0.63% to $594.20, while the QQQ advanced 0.44% to $521.51, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45433051/jim-cramer-says-gulf-countries-will-become-the-largest-hyperscalers-in-the-world-following-ai-deals">Jim Cramer Says Gulf Countries Will Become &#8216;Largest Hyperscalers In The World&#8217; After Nvidia&#8217;s 18,000 Blackwell Chip Deal</a></li>
</ul>
Photo courtesy: Rawpixel.com / Shutterstock.com

Health Care

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion

An official report on May 14, 2025 reveals Representative Julie Johnson's recent sale of Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) stock, valued between $223,139 and $2,295,000. The transaction took place on May 14, 2025, as per the May filing.
At this time, Amazon.com shares are trading down 3.06% at $203.82.
<h3>Representative's Recent Trading Activity</h3>
Over the previous three years, Julie Johnson conducted 119 trades, totaling more than $133 thousand. The largest of these were in Tesla and ALLETE stock. Some of the most notable transactions the Rep. has executed recently include: 
<ul>
<li>Capital One Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>): $1,001 - $15,000 Purchase</li>
<li>Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>): $1,001 - $15,000 Sale</li>
<li>Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>): $1,001 - $15,000 Purchase</li>
</ul>
Here's a summary of Julie Johnson's most recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capital One Finl</td>
<td>COF</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-03-21</td>
</tr>
<tr>
<td>Accenture</td>
<td>ACN</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-03-19</td>
</tr>
<tr>
<td>Cigna Group</td>
<td>CI</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-03-19</td>
</tr>
<tr>
<td>Accenture</td>
<td>ACN</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S (Partial)</td>
<td>2025-03-14</td>
</tr>
<tr>
<td>3M</td>
<td>MMM</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-03-12</td>
</tr>
</tbody>
</table>
Stay informed on Julie Johnson's trades and other members of Congress with our real-time <a href="https://www.benzinga.com/gov-trades/members/julie-johnson">government trades tracking tool</a>!
<h3>The Importance of Congressional Transactions</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Government

Texas Rep. Julie Johnson Sold Up to $2.29M Worth of Amazon.com Stock

President Donald Trump on Monday signed a sweeping executive order aimed at drastically reducing prescription <a href="https://www.benzinga.com/topic/drug-prices">drug prices in the U.S. </a>
What Happened: The Trump administration wants to tie drug prices to the lowest amount paid in comparable foreign countries — a policy known as <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45381118/cvs-health-cigna-stocks-dip-tuesday-whats-going-on">&#8220;most-favored-nation&#8221; pricing.</a>
The executive order is <a href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-put-american-patients-first-by-lowering-drug-prices-and-stopping-foreign-free-riding-on-american-pharmaceutical-innovation/">a response</a> to what Trump described as &#8220;unreasonable or discriminatory&#8221; practices abroad. 
"In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism aboard [abroad] with skyrocketing prices at home," Trump said in <a href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-put-american-patients-first-by-lowering-drug-prices-and-stopping-foreign-free-riding-on-american-pharmaceutical-innovation/">a statement</a>.&nbsp;
Drug manufacturers have 30 days to voluntarily lower prices for prescription drugs in the U.S. to match those paid in other advanced nations.&nbsp;
If companies do not comply, the Department of Health and Human Services, led by Robert F. Kennedy Jr., is tasked with developing rules to enforce most-favored nation (MFN) pricing or other regulatory measures.&nbsp;
The HHS is also instructed to establish mechanisms for Americans to purchase drugs directly from manufacturers at the MFN price, bypassing pharmacy benefit managers (PBMs) and other intermediaries.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/05/45378427/trump-wants-to-kickstart-nuclear-development-these-5-stocks-could-boom?utm_source=articleShare">Trump Wants To Kickstart Nuclear Development: These 5 Stocks Could Boom</a>&nbsp;
Why It Matters: The executive order is a rare show of common ground between the Trump administration and Democratic leaders like Senator Bernie Sanders, who has long fought for laws aimed at making medicine more affordable.
And Trump has tried this before. During his first term, he signed a similar <a href="https://trumpwhitehouse.archives.gov/presidential-actions/executive-order-lowering-drug-prices-putting-america-first-2/">order</a> that the courts ultimately blocked after the pharmaceutical industry lobbied against it.
Sanders fears the same thing might happen again. In a <a href="https://bsky.app/profile/did:plc:upw5n2uwhzubjajdtqaufsek/post/3loyh44tra225?ref_src=embed&amp;ref_url=https%253A%252F%252Fwww.commondreams.org%252Fnews%252Ftrump-executive-order-drug-prices">post</a> on the Bluesky social network, he agreed that it is &#8220;an outrage that the American people pay, by far, the highest prices in the world for prescription drugs.&#8221;
&#8220;As Trump well knows, his executive order will be thrown out by the courts,&#8221; said Sanders. &#8220;If Trump is serious about making real change rather than just issuing a press release, he will support legislation I will soon be introducing to make sure we pay no more for prescription drugs than people in other major countries. If Republicans and Democrats come together on this legislation, we can get it passed in a few weeks.&#8221;
Pharmaceutical stocks dropped in Monday's premarket trading, but recovered into positive territory by the market close.
Analysts and investors decided the order was less-specific than feared and likely to be challenged in court.&nbsp;
"A drug pricing announcement had been expected for a while now and had weighed on stocks in this sector, so the official executive order doesn&#8217;t seem to be impacting sentiment too much,&#8221; said James Harlow, senior vice president at Novare Capital Management, per Reuters.&nbsp;
In contrast, Trump&#8217;s comments of &#8220;cutting out the middlemen&#8221; weighed on shares of companies that own pharmacy benefit managers like The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) and UnitedHeath Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>).&nbsp;
"I would cut out the middlemen," Trump said. "Everybody should equalize. Everybody should pay the same price."
Shares of UnitedHealth plunged Tuesday after<a href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance"> the company</a> pulled its 2025 outlook, citing that care activity continued to accelerate and CEO Andrew Witty unexpectedly resigned.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/05/45354683/tesla-probably-wont-make-money-on-ride-hailing-for-years-gary-black-says?utm_source=articleShare">Tesla Robotaxi Hopes Dashed By Uber, Lyft: No Fast Lane To Profits, Warns Investor Gary Black&nbsp;</a>
What To Watch: The executive order threatens the PBM business model by enabling direct-to-consumer drug purchases, which could significantly reduce the need for PBMs&#8217; negotiating and administrative services. However, legal experts have raised concerns about the legality of direct-to-consumer sales.&nbsp;
"This order's suggestion of broader or direct-to-consumer importation stretches well beyond what the statute allows," warned health policy lawyer, Paul Kim, per the New York Post.&nbsp;
Investors in the healthcare sector may choose to mitigate risk and exposure to PBMs through a diversified healthcare ETF like the SPDR Select Health Care Sector Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) which holds shares of pharmaceuticals, health care equipment and supplies and health care providers.&nbsp;
An ETF like the iShares U.S. Medical Devices ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITI#NYSE">ITI</a>) which tracks the Dow Jones U.S. Select Medical Equipment Index and invests in leading U.S. medical device companies also offers exposure to the healthcare industry while reducing exposure to pharmaceutical benefit managers.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45319531/cathie-wood?utm_source=articleShare">Cathie Wood Says AI Will &#8216;Disrupt The Traditional World Order&#8217; And Replace Search Engines Like Google</a>&nbsp;</li>
</ul>
Image: Shutterstock

Comments

Cigna Group

Unusual Options Activity for

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL